What type of study is this?

December 8, 2025BloodOpen Access

Low-dose chemotherapy for induction in pediatric AML: Retrospective outcome analysis across expanded cohorts

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reports comparable long-term outcomes; low-dose chemotherapy may reduce toxicity in pediatric AML.

Complete remission rates were similar in low-dose and standard-dose chemotherapy for pediatric AML.
4-year overall survival rates were 83.5% for low-dose chemotherapy versus 85.0% for standard-dose chemotherapy.
Analysis of toxicity revealed that low-dose chemotherapy resulted in fewer grade 3-4 toxicities compared to standard-dose chemotherapy.
Findings suggest that low-dose chemotherapy may be beneficial, especially in younger patients and those with specific genetic mutations.

Zhai et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark